Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program
ALKS(NASDAQ:ALKS) — Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project — — Areas of Interest Expanded to Include Sleep and Circadian Disturbances Associated With Bipolar I Disorder and/or Schizophrenia — — Application Period to Run From Sept. 15, 2025 Through Dec. 15, 2025 —...
Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025
ALKS– Results From Vibrance-1 to Be Shared in Three Oral Presentations, Including Primary and Secondary Efficacy and Safety Measures, and Exploratory Patient-Reported Outcomes Related to Disease Severity, Fatigue and Cognition – – Company to Host Investor Webcast on Monday, Sept. 8 at 8:00...
Alkermes Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
ALKSNeedham Initiates Coverage On Alkermes with Buy Rating, Announces Price Target of $45
ALKSRBC Capital Maintains Sector Perform on Alkermes, Raises Price Target to $40
ALKSBaird Maintains Outperform on Alkermes, Raises Price Target to $41
ALKSAlkermes Affirms FY2025 GAAP EPS Guidance of $1.03-$1.21 vs $1.12 Est; Affirms FY2025 Sales Guidance of $1.34B-$1.43B vs $1.39B Est
ALKSAlkermes Q1 GAAP EPS $0.13 Beats $0.05 Estimate, Sales $306.51M Beat $304.12M Estimate
ALKSBeyond The Numbers: 6 Analysts Discuss Alkermes Stock
ALKSUBS Maintains Neutral on Alkermes, Lowers Price Target to $33
ALKSAlkermes Has Initiated Vibrance-3 Phase 2 Study Evaluating The Safety And Efficacy Of ALKS 2680 Compared To Placebo In Adults With Idiopathic Hypersomnia
ALKSWhat 5 Analyst Ratings Have To Say About Alkermes
ALKSDeutsche Bank Maintains Buy on Alkermes, Raises Price Target to $52
ALKSRBC Capital Initiates Coverage On Alkermes with Sector Perform Rating, Announces Price Target of $40
ALKSGoldman Sachs Maintains Buy on Alkermes, Raises Price Target to $32
ALKSHC Wainwright & Co. Reiterates Neutral on Alkermes, Maintains $46 Price Target
ALKSAlkermes Forecasts 2025 Sales Of $1.34B-$1.43B Versus Consensus Of $1.40B
ALKSAlkermes Q4 2024 Adj EPS $1.04 Beats $0.79 Estimate, Sales $429.99M Beat $379.74M Estimate
ALKSAlkermes FY 2024 Adj EPS $2.92 Beats $2.66 Estimate, Sales $1.56B Beat $1.51B Estimate
ALKSCharter Communications To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Tuesday
ALKSA Glimpse Into The Expert Outlook On Alkermes Through 9 Analysts
ALKSStifel Upgrades Alkermes to Buy, Raises Price Target to $36
ALKSLooking Into Alkermes's Return On Capital Employed
ALKSBenzinga Pro data, Alkermes (NASDAQ:ALKS) reported Q1 sales of $278.55 million. Earnings fell to a loss of $35.90 million, resulting in a 4212.6% decrease from last quarter.
SVB Leerink Maintains Market Perform on Alkermes, Raises Price Target to $27
ALKSHC Wainwright & Co. Maintains Neutral on Alkermes, Raises Price Target to $32
ALKS